Amanote Research
Register
Sign In
Defining Value When Launching Biosimilars Treatments Within European Healthcare Systems
Value in Health
- United Kingdom
doi 10.1016/j.jval.2015.09.1677
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
November 1, 2015
Authors
R White
O Staples
Publisher
Elsevier BV
Related search
PSY15 Striving for Affordable Treatments Within the Greek Environment: Do Epoetin Biosimilars Help?
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Hospice Collaboration and Integration Within Large Healthcare Systems (TH334)
Journal of Pain and Symptom Management
Neurology
Anesthesiology
Pain Medicine
Nursing
A European Perspective on the Market Accessibility of Biosimilars
Biosimilars
Tendering and Biosimilars: What Role for Value-Added Services?
Journal of Market Access & Health Policy
The Role of Biosimilars in Value-Based Oncology Care
Cancer Management and Research
Oncology
Defining Patient Value in Haemophilia Care
Haemophilia
Medicine
Genetics
Hematology
Defining Futile Life-Prolonging Treatments Through Neo-Socratic Dialogue
BMC Medical Ethics
Health Policy
Ethics
Health
Issues
Legal Aspects
How Are Fast-Track Programmes Like Rapid Recovery Delivering Value Across Hospitals, Cultures and Healthcare Systems in Orthopedics Within a Cost-Constrained Environment?
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Reimbursement of Targeted Cancer Therapies Within Three Different European Health Care Systems
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
